

<b>Hold</b> (Buy) <b>EUR 21.70</b> (EUR 16.90)  Price EUR 19.58 <b>Upside 10.8 %</b>	<b>Value Indicators:</b> EUR DCF: 21.67 FCF-Value Potential: 32.73	<b>Share data:</b> Bloomberg: M3V GR Reuters: M3VG ISIN: DE000A0LBFE4	<b>Description:</b> A leading supplier of software for visual-based medical equipment
	<b>Market Snapshot:</b> EUR m Market cap: 35.6 No. of shares (m): 1.8 EV: 22.2 Freefloat MC: 7.4 Ø Trad. Vol. (30d): 16.60 th	<b>Shareholders:</b> Freefloat 20.7 % Others 22.7 % Prof. Dr. Heinz-Otto Peitgen 19.4 % Dr. Hartmut Jürgens 16.5 % Dr. Carl J. G. Evertsz 15.3 %	<b>Risk Profile (WRe):</b> 2013e Beta: 1.8 Price / Book: 1.3 x Equity Ratio: 76 % Net Fin. Debt / EBITDA: -1.8 x Net Debt / EBITDA: -1.8 x

## Earnings increase already anticipated

On 04.11.13. MeVis Medical Solutions AG announced a modification of its company outlook ahead of the Q3 figures. This included two important points:

- Expectation of a **revenue increase** (previously: "stable revenue") and a **clear increase in EBIT** (previously: "increase"). This adjustment is covered by the earlier release of good Q2 figures. With the continuation of the strong demand especially in the area of tomosynthesis, the adjustment seems more realistic than the previous guidance. In light of apparently steady high demand, the WR forecasts are also increased again. Here it must be noted that it mainly concerns licence approvals on the part of Hologic. In the past these were subject to high volatility.
- Over and above that, an increase in costs is expected **"Increase in Resources"**. The main news here is that the large customer Hologic (revenue share ca. 65%) is apparently demanding a technical improvement in the products. Whether this expansion of the development capacities can be compensated for by higher revenues in the coming year is not certain. Development costs account for about 80% (directly and indirectly) of the total costs at MeVis. These fixed cost positions face mainly volatile licence income.

Overall, there is currently no clear picture. While the **last quarterly figures were very convincing throughout**, the operating performance remains the central argument for the share. Also for Q3, a very good result is expected. The full year 2013 should stand out strongly for its good licence business and disciplined cost policy. On the other hand, a rise in costs is expected again for 2014. Since 2010, the operating expenses have constantly decreased. This went hand in hand with a reduction in development capacity. This trend will reverse as of 2014. To achieve the same results, the dependency on licence income rises further.

Against the background of the extremely good share price development since the share was upgraded (30.04.13 ca. +120%), the current share price level now already anticipates high earnings strength and company stability. **Despite the further increase in revenue and earnings estimates (WR) the share is therefore now rated at Hold.**

Changes in Estimates:						Comment on Changes:	
FY End: 31.12. in EUR m	2013e (old)	+ / -	2014e (old)	+ / -	2015e (old)	+ / -	
Sales	13.5	3.7 %	13.4	12.2 %	13.2	17.4 %	Based on strong demand for tomosynthesis solutions, an adjustment of the revenue forecasts 2013ff was carried out.
EBITDA	6.6	11.7 %	6.3	17.5 %	6.1	23.1 %	Mainly in 2013, this is reflected in far higher earnings thanks to distinct cost control.
EBIT	3.4	19.1 %	3.2	22.6 %	3.0	28.9 %	As of 2014, higher costs are anticipated and despite rising revenue, it is expected that earnings will only remain stable.
EBT	3.4	18.8 %	3.3	22.0 %	3.1	28.0 %	
Net income	3.3	18.8 %	3.0	22.0 %	2.7	28.0 %	




Rel. Performance vs CDAX:	
1 month:	13.2 %
6 months:	81.7 %
Year to date:	112.9 %
Trailing 12 months:	85.1 %

Company events:	
11.11.13	Q3


FY End: 31.12. in EUR m	CAGR (12-15e)	2009	2010	2011	2012	2013e	2014e	2015e
Sales	5.1 %	13.9	14.3	13.7	13.3	14.0	15.0	15.5
Change Sales yoy		27.9 %	3.0 %	-4.3 %	-2.4 %	4.9 %	7.1 %	3.3 %
Gross profit margin		113.3 %	114.7 %	112.3 %	114.1 %	109.9 %	108.7 %	108.0 %
EBITDA	8.1 %	4.5	3.5	4.4	6.0	7.3	7.5	7.5
Margin		32.3 %	24.2 %	32.3 %	44.6 %	52.3 %	49.7 %	48.6 %
EBIT	9.3 %	1.6	-5.4	-1.6	3.0	4.0	3.9	3.9
Margin		11.8 %	-38.0 %	-12.0 %	22.3 %	28.8 %	26.2 %	25.1 %
Net income	17.5 %	0.4	-8.3	-4.1	2.2	3.9	3.7	3.5
EPS	17.4 %	0.23	-4.89	-2.38	1.26	2.26	2.16	2.04
EPS adj.	17.4 %	0.23	-4.89	-2.38	1.26	2.26	2.16	2.04
DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
FCFPS		0.02	1.04	1.34	1.56	3.27	3.16	2.87
EV / Sales		2.9 x	2.2 x	0.7 x	0.3 x	1.6 x	1.1 x	0.8 x
EV / EBITDA		9.0 x	9.3 x	2.2 x	0.6 x	3.0 x	2.2 x	1.6 x
EV / EBIT		24.7 x	n.a.	n.a.	1.2 x	5.5 x	4.3 x	3.0 x
P / E		102.1 x	n.a.	n.a.	5.2 x	8.7 x	9.1 x	9.6 x
P / E adj.		102.1 x	n.a.	n.a.	5.2 x	8.7 x	9.1 x	9.6 x
FCF Yield Potential		1.9 %	-7.7 %	3.2 %	93.3 %	25.8 %	34.3 %	47.9 %
Net Debt		-0.6	-0.7	-2.8	-7.8	-13.5	-18.9	-23.9
ROE		1.2 %	-29.1 %	-18.0 %	9.9 %	15.7 %	13.0 %	10.9 %
ROCE (NOPAT)		1.7 %	-28.8 %	-11.0 %	16.6 %	27.2 %	29.4 %	31.8 %
Guidance:	Improvement of revenues, significant improvement of EBIT							

**Sales development**  
in EUR m




Source: Warburg Research

**Sales by types**  
2011; in %



Source: Warburg Research

**EBIT development**  
in EUR m



Source: Warburg Research


## Company Background

- The origin of MeVis Medical Solutions AG, which was set up in 1998, dates back to 1992, when the CeVis (Center for Complex Systems and Visualization) was founded at the University of Bremen.
- The public company was founded with the aim of developing commercially successful disease-oriented products based on successes in scientific research and to market these.
- Since its foundation, MeVis has been active in the area of computer-aided, image-based medical diagnostics and therapy.
- MeVis has successfully risen to become a globally-leading provider of software solutions for medical imaging. This development is mainly based on the success in the area of digital mammography.
- Together with products by Hologic and Siemens, MeVis's solutions dominate this segment today. Furthermore, MeVis has a broad portfolio of new products.

## Competitive Quality


- MeVis follows a strategy of early market presence in the new areas of image-based medical technology. In focus here are mass market products.
- The ability to be an early market entrant differentiates MeVis from competitors.
- MeVis maintains long-term and interdisciplinary cooperation agreements with more than 100 hospitals and leading R&D centres in Germany, Europe, the US and Asia.
- MeVis fosters partnerships with the globally leading medical technology OEMs, for instance Siemens and Hologic.

**EBT development**  
in EUR m




Source: Warburg Research

**Sales by segments**  
2011; in %



Source: Warburg Research

**Net income development**  
in EUR m



Source: Warburg Research

**DCF model**

Figures in EUR m	Detailed forecast period			Transitional period										Term. Value
	2013e	2014e	2015e	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	
Sales	14.0	15.0	15.5	15.4	15.3	15.3	15.2	15.1	15.0	15.0	14.9	14.8	14.7	0.0 %
Sales change	4.9 %	7.1 %	3.3 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	-0.5 %	
EBIT	4.0	3.9	3.9	3.5	3.5	3.5	3.5	3.5	3.4	3.4	3.3	3.2	3.2	21.5 %
EBIT-margin	28.8 %	26.2 %	25.1 %	23.0 %	23.0 %	23.0 %	23.0 %	23.0 %	22.7 %	22.4 %	22.1 %	21.8 %	21.5 %	
Tax rate (EBT)	5.0 %	8.0 %	12.0 %	20.0 %	20.0 %	20.0 %	20.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	2.4
NOPAT	3.8	3.6	3.4	2.8	2.8	2.8	2.8	2.6	2.6	2.5	2.5	2.4	2.4	
Depreciation	3.3	3.5	3.6	3.4	3.4	3.2	3.0	2.9	2.7	2.5	2.4	2.2	2.1	14.0 %
in % of Sales	23.5 %	23.5 %	23.5 %	22.0 %	22.0 %	21.0 %	20.0 %	19.0 %	18.0 %	17.0 %	16.0 %	15.0 %	14.0 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in Liquidity from														
- Working Capital	-0.5	-0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1
- Capex	2.1	2.1	2.1	3.4	3.4	3.2	3.0	2.9	2.7	2.5	2.4	2.2	2.1	
Capex in % of Sales	14.9 %	14.0 %	13.6 %	22.0 %	22.0 %	21.0 %	20.0 %	19.0 %	18.0 %	17.0 %	16.0 %	15.0 %	14.0 %	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	5.6	5.3	4.9	2.7	2.8	2.8	2.8	2.6	2.6	2.5	2.5	2.4	2.4	4
PV of FCF	5.6	4.8	3.8	1.9	1.8	1.6	1.4	1.2	1.0	0.9	0.8	0.7	0.6	
share of PVs	47.25 %			39.13 %										13.62 %

**Model parameter**

Derivation of WACC:

Debt ratio	0.00 %
Cost of debt	4.2 %
Market return	8.00 %
Risk free rate	2.50 %

Derivation of Beta:

Financial Strength	1.00
Liquidity	2.00
Cyclicality	2.00
Transparency	2.00
Others	2.00

**WACC** 12.40 %**Beta** 1.80**Valuation (m)**

Present values 2025e

26

Terminal Value

4

Financial liabilities

-1

Pension liabilities

0

Hybrid capital

0

Minority interest

0

Market val. of investments

0

Liquidity

9

No. of shares (m)

1.8

**Equity Value****39****Value per share (EUR)****21.67****Sensitivity Value per Share (EUR)**

		Terminal Growth									Delta EBIT-margin						
Beta	WACC	-0.75 %	-0.50 %	-0.25 %	0.00 %	0.25 %	0.50 %	0.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.98	13.4 %	20.78	20.81	20.84	20.87	20.91	20.95	20.98	1.98	13.4 %	20.04	20.32	20.60	20.87	21.15	21.43	21.71
1.89	12.9 %	21.14	21.18	21.22	21.26	21.30	21.34	21.38	1.89	12.9 %	20.40	20.69	20.97	21.26	21.54	21.83	22.11
1.85	12.7 %	21.34	21.38	21.42	21.46	21.50	21.55	21.59	1.85	12.7 %	20.59	20.88	21.17	21.46	21.75	22.04	22.33
1.80	12.4 %	21.54	21.58	21.62	21.67	21.71	21.76	21.81	1.80	12.4 %	20.78	21.08	21.37	21.67	21.96	22.25	22.55
1.75	12.2 %	21.75	21.79	21.83	21.88	21.93	21.98	22.04	1.75	12.2 %	20.98	21.28	21.58	21.88	22.18	22.48	22.78
1.71	11.9 %	21.96	22.01	22.06	22.11	22.16	22.22	22.27	1.71	11.9 %	21.19	21.50	21.80	22.11	22.41	22.72	23.02
1.62	11.4 %	22.42	22.47	22.53	22.58	22.64	22.71	22.77	1.62	11.4 %	21.64	21.95	22.27	22.58	22.90	23.21	23.53

■ The DCF model bases on the assumption of slightly decreasing revenues and earnings in the years to come.

Valuation							
	2009	2010	2011	2012	2013e	2014e	2015e
Price / Book	1.3 x	1.3 x	0.6 x	0.5 x	1.3 x	1.2 x	1.1 x
Book value per share ex intangibles	3.17	1.63	1.05	3.44	6.24	9.05	11.79
EV / Sales	2.9 x	2.2 x	0.7 x	0.3 x	1.6 x	1.1 x	0.8 x
EV / EBITDA	9.0 x	9.3 x	2.2 x	0.6 x	3.0 x	2.2 x	1.6 x
EV / EBIT	24.7 x	n.a.	n.a.	1.2 x	5.5 x	4.3 x	3.0 x
EV / EBIT adj.*	24.7 x	n.a.	n.a.	1.2 x	5.5 x	4.3 x	3.0 x
P / FCF	n.a.	18.5 x	5.4 x	4.2 x	6.0 x	6.2 x	6.8 x
P / E	102.1 x	n.a.	n.a.	5.2 x	8.7 x	9.1 x	9.6 x
P / E adj.*	102.1 x	n.a.	n.a.	5.2 x	8.7 x	9.1 x	9.6 x
Dividend Yield	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Free Cash Flow Yield Potential	1.9 %	-7.7 %	3.2 %	93.3 %	25.8 %	34.3 %	47.9 %
*Adjustments made for: -							

## Consolidated profit & loss

In EUR m	2009	2010	2011	2012	2013e	2014e	2015e
<b>Sales</b>	<b>13.9</b>	<b>14.3</b>	<b>13.7</b>	<b>13.3</b>	<b>14.0</b>	<b>15.0</b>	<b>15.5</b>
Change Sales yoy	27.9 %	3.0 %	-4.3 %	-2.4 %	4.9 %	7.1 %	3.3 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	2.3	2.8	2.4	2.4	1.8	1.8	1.8
<b>Total Sales</b>	<b>16.2</b>	<b>17.1</b>	<b>16.1</b>	<b>15.8</b>	<b>15.8</b>	<b>16.8</b>	<b>17.3</b>
Material Expenses	0.5	0.7	0.7	0.5	0.4	0.5	0.6
<b>Gross profit</b>	<b>15.7</b>	<b>16.4</b>	<b>15.4</b>	<b>15.2</b>	<b>15.4</b>	<b>16.3</b>	<b>16.7</b>
<i>Gross profit margin</i>	<i>113.3 %</i>	<i>114.7 %</i>	<i>112.3 %</i>	<i>114.1 %</i>	<i>109.9 %</i>	<i>108.7 %</i>	<i>108.0 %</i>
Personnel expenses	9.8	10.4	9.2	8.1	7.5	8.2	8.5
Other operating income	1.8	1.1	1.1	1.1	1.1	1.2	1.2
Other operating expenses	3.3	3.7	2.9	2.3	1.7	1.8	2.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>EBITDA</b>	<b>4.5</b>	<b>3.5</b>	<b>4.4</b>	<b>6.0</b>	<b>7.3</b>	<b>7.5</b>	<b>7.5</b>
<i>Margin</i>	<i>32.3 %</i>	<i>24.2 %</i>	<i>32.3 %</i>	<i>44.6 %</i>	<i>52.3 %</i>	<i>49.7 %</i>	<i>48.6 %</i>
Depreciation of fixed assets	0.5	5.8	3.0	0.5	0.6	0.6	0.6
<b>EBITA</b>	<b>3.9</b>	<b>-2.3</b>	<b>1.5</b>	<b>5.5</b>	<b>6.8</b>	<b>6.9</b>	<b>6.9</b>
Amortisation of intangible assets	2.3	3.1	3.1	2.5	2.7	2.9	3.0
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>EBIT</b>	<b>1.6</b>	<b>-5.4</b>	<b>-1.6</b>	<b>3.0</b>	<b>4.0</b>	<b>3.9</b>	<b>3.9</b>
<i>Margin</i>	<i>11.8 %</i>	<i>-38.0 %</i>	<i>-12.0 %</i>	<i>22.3 %</i>	<i>28.8 %</i>	<i>26.2 %</i>	<i>25.1 %</i>
<b>EBIT adj.</b>	<b>1.6</b>	<b>-5.4</b>	<b>-1.6</b>	<b>3.0</b>	<b>4.0</b>	<b>3.9</b>	<b>3.9</b>
Interest income	0.6	0.4	0.1	0.1	0.1	0.1	0.1
Interest expenses	1.0	0.7	0.3	0.3	0.0	0.0	0.0
Other financial income (loss)	-0.1	0.1	-1.0	-0.3	0.0	0.0	0.0
<b>EBT</b>	<b>1.2</b>	<b>-5.6</b>	<b>-2.9</b>	<b>2.4</b>	<b>4.1</b>	<b>4.0</b>	<b>4.0</b>
<i>Margin</i>	<i>8.4 %</i>	<i>-39.2 %</i>	<i>-21.3 %</i>	<i>17.7 %</i>	<i>29.2 %</i>	<i>26.9 %</i>	<i>25.7 %</i>
Total taxes	0.8	2.7	1.2	0.2	0.2	0.3	0.5
<b>Net income from continuing operations</b>	<b>0.4</b>	<b>-8.3</b>	<b>-4.1</b>	<b>2.2</b>	<b>3.9</b>	<b>3.7</b>	<b>3.5</b>
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Net income before minorities</b>	<b>0.4</b>	<b>-8.3</b>	<b>-4.1</b>	<b>2.2</b>	<b>3.9</b>	<b>3.7</b>	<b>3.5</b>
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Net income</b>	<b>0.4</b>	<b>-8.3</b>	<b>-4.1</b>	<b>2.2</b>	<b>3.9</b>	<b>3.7</b>	<b>3.5</b>
<i>Margin</i>	<i>2.9 %</i>	<i>-58.4 %</i>	<i>-29.9 %</i>	<i>16.2 %</i>	<i>27.8 %</i>	<i>24.7 %</i>	<i>22.6 %</i>
Number of shares, average	1.7	1.7	1.7	1.7	1.7	1.7	1.7
<b>EPS</b>	<b>0.23</b>	<b>-4.89</b>	<b>-2.38</b>	<b>1.26</b>	<b>2.26</b>	<b>2.16</b>	<b>2.04</b>
EPS adj.	0.23	-4.89	-2.38	1.26	2.26	2.16	2.04

\*Adjustments made for:


**Guidance: Improvement of revenues, significant improvement of EBIT**

## Financial Ratios

	2009	2010	2011	2012	2013e	2014e	2015e
Total Operating Costs / Sales	84.4 %	95.3 %	85.2 %	73.5 %	60.6 %	62.3 %	63.0 %
Operating Leverage	5.2 x	n.a.	16.3 x	n.a.	7.2 x	-0.3 x	-0.4 x
EBITDA / Interest expenses	4.5 x	4.8 x	12.8 x	17.2 x	n.a.	n.a.	n.a.
Tax rate (EBT)	65.9 %	-48.9 %	-40.4 %	8.3 %	5.0 %	8.0 %	12.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	58,029	63,799	102,075	119,170	127,273	133,929	138,393


## Sales, EBITDA

in EUR m




## Operating Performance

in %



## Performance per Share



Source: Warburg Research

Source: Warburg Research




Source: Warburg Research

**Consolidated balance sheet**

In EUR m	2009	2010	2011	2012	2013e	2014e	2015e
<b>Assets</b>							
Goodwill and other intangible assets	27.1	22.0	18.9	16.8	15.9	14.8	13.6
thereof other intangible assets	10.5	9.4	6.3	6.2	5.3	4.2	2.9
thereof Goodwill	16.6	12.6	12.6	10.6	10.6	10.6	10.6
Property, plant and equipment	1.2	0.9	0.7	0.3	0.0	-0.3	-0.6
Financial assets	0.0	1.3	0.3	0.3	0.3	0.3	0.3
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Fixed assets</b>	<b>28.3</b>	<b>24.2</b>	<b>19.9</b>	<b>17.5</b>	<b>16.3</b>	<b>14.9</b>	<b>13.3</b>
Inventories	0.1	0.1	0.3	0.2	0.1	0.1	0.1
Accounts receivable	4.2	5.1	4.4	3.9	3.5	3.3	3.4
Liquid assets	15.1	8.2	7.5	8.7	14.3	19.7	24.7
Other short-term assets	3.2	1.2	0.5	0.7	0.7	0.7	0.7
<b>Current assets</b>	<b>22.7</b>	<b>14.6</b>	<b>12.7</b>	<b>13.4</b>	<b>18.6</b>	<b>23.8</b>	<b>28.9</b>
<b>Total Assets</b>	<b>51.0</b>	<b>38.8</b>	<b>32.5</b>	<b>30.9</b>	<b>34.9</b>	<b>38.7</b>	<b>42.2</b>
<b>Liabilities and shareholders' equity</b>							
Subscribed capital	1.8	1.8	1.8	1.8	1.8	1.8	1.8
Capital reserve	28.5	28.5	28.1	28.1	28.1	28.1	28.1
Retained earnings	0.0	0.0	0.0	0.0	3.9	7.6	11.1
Other equity components	2.3	-5.5	-9.2	-7.1	-7.1	-7.1	-7.1
Shareholder's equity	32.6	24.8	20.7	22.8	26.7	30.4	33.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total equity</b>	<b>32.6</b>	<b>24.8</b>	<b>20.7</b>	<b>22.8</b>	<b>26.7</b>	<b>30.4</b>	<b>33.9</b>
Provisions	0.2	1.1	1.1	0.8	0.8	0.8	0.8
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	14.5	7.5	4.7	0.8	0.8	0.8	0.8
thereof short-term financial liabilities	0.4	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.1	1.3	1.2	1.1	1.2	1.3	1.3
Other liabilities	2.6	4.2	4.8	5.4	5.4	5.4	5.4
<b>Liabilities</b>	<b>18.3</b>	<b>14.0</b>	<b>11.8</b>	<b>8.1</b>	<b>8.2</b>	<b>8.3</b>	<b>8.3</b>
<b>Total liabilities and shareholders' equity</b>	<b>51.0</b>	<b>38.8</b>	<b>32.5</b>	<b>30.9</b>	<b>34.9</b>	<b>38.7</b>	<b>42.2</b>

**Financial Ratios**

	2009	2010	2011	2012	2013e	2014e	2015e
<b>Efficiency of Capital Employment</b>							
Operating Assets Turnover	3.1 x	3.0 x	3.3 x	4.1 x	5.7 x	8.2 x	9.5 x
Capital Employed Turnover	0.4 x	0.6 x	0.8 x	0.9 x	1.1 x	1.3 x	1.5 x
ROA	1.4 %	-34.5 %	-20.6 %	12.4 %	23.9 %	25.0 %	26.3 %
<b>Return on Capital</b>							
ROCE (NOPAT)	1.7 %	-28.8 %	-11.0 %	16.6 %	27.2 %	29.4 %	31.8 %
ROE	1.2 %	-29.1 %	-18.0 %	9.9 %	15.7 %	13.0 %	10.9 %
Adj. ROE	1.2 %	-29.1 %	-18.0 %	9.9 %	15.7 %	13.0 %	10.9 %
<b>Balance sheet quality</b>							
Net Debt	-0.6	-0.7	-2.8	-7.8	-13.5	-18.9	-23.9
Net Financial Debt	-0.6	-0.7	-2.8	-7.8	-13.5	-18.9	-23.9
Net Gearing	-1.9 %	-2.8 %	-13.5 %	-34.4 %	-50.5 %	-62.3 %	-70.4 %
Net Fin. Debt / EBITDA	-13.8 %	-20.4 %	-63.3 %	-131.6 %	-184.0 %	-253.5 %	-316.8 %
Book Value / Share	18.7	14.5	12.0	13.2	15.5	17.6	19.7
Book value per share ex intangibles	3.2	1.6	1.1	3.4	6.2	9.0	11.8

**ROCE Development****Net debt in EUR m****Book Value per Share in EUR**

Source: Warburg Research

Source: Warburg Research




Source: Warburg Research

**Consolidated cash flow statement**

In EUR m	2009	2010	2011	2012	2013e	2014e	2015e
Net income	-0.2	-5.3	-1.3	3.1	3.9	3.7	3.5
Depreciation of fixed assets	0.5	5.8	3.0	0.5	0.6	0.6	0.6
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	2.3	3.1	3.1	2.5	2.7	2.9	3.0
Increase/decrease in long-term provisions	0.1	0.9	0.0	-0.4	0.0	0.0	0.0
Other non-cash income and expenses	0.1	-0.4	0.0	0.1	0.0	0.0	0.0
<b>Cash Flow</b>	<b>2.8</b>	<b>4.0</b>	<b>4.8</b>	<b>5.7</b>	<b>7.2</b>	<b>7.2</b>	<b>7.2</b>
Increase / decrease in inventory	0.0	0.0	-0.2	0.1	0.1	0.0	0.0
Increase / decrease in accounts receivable	1.9	-0.5	1.0	0.1	0.4	0.2	-0.1
Increase / decrease in accounts payable	-1.6	1.4	-0.5	-0.6	0.1	0.1	0.0
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	0.3	0.9	0.4	-0.4	0.5	0.3	-0.1
<b>Net cash provided by operating activities</b>	<b>3.1</b>	<b>5.0</b>	<b>5.1</b>	<b>5.3</b>	<b>7.7</b>	<b>7.5</b>	<b>7.1</b>
Investments in intangible assets	-2.7	-3.0	-2.7	-2.5	-1.8	-1.8	-1.8
Investments in property, plant and equipment	-0.3	-0.2	-0.1	-0.1	-0.3	-0.3	-0.3
Payments for acquisitions	-4.7	-7.2	-3.0	-1.4	0.0	0.0	0.0
Financial investments	-2.3	3.9	1.1	0.9	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Net cash provided by investing activities</b>	<b>-10.0</b>	<b>-6.5</b>	<b>-4.7</b>	<b>-3.1</b>	<b>-2.1</b>	<b>-2.1</b>	<b>-2.1</b>
Change in financial liabilities	-0.1	-0.4	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	-0.5	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Net cash provided by financing activities</b>	<b>-0.5</b>	<b>-0.4</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
Change in liquid funds	-7.4	-2.0	0.4	2.1	5.6	5.4	4.9
Effects of exchange-rate changes on cash	-0.1	-0.1	0.1	-0.1	0.0	0.0	0.0
<b>Cash and cash equivalent at end of period</b>	<b>7.7</b>	<b>5.6</b>	<b>6.1</b>	<b>8.1</b>	<b>13.8</b>	<b>19.2</b>	<b>24.2</b>

**Financial Ratios**

	2009	2010	2011	2012	2013e	2014e	2015e
<b>Cash Flow</b>							
Free Cash Flow	0.0	1.8	2.3	2.7	5.6	5.4	4.9
Free Cash Flow / Sales	0.2 %	12.4 %	16.9 %	20.1 %	40.3 %	36.2 %	31.9 %
Free Cash Flow Potential	0.8	-2.5	0.3	3.2	5.7	5.7	5.7
Free Cash Flow / Sales	0.2 %	12.4 %	16.9 %	20.1 %	40.3 %	36.2 %	31.9 %
Free Cash Flow / Net Profit	7.8 %	-21.2 %	-56.4 %	124.3 %	145.0 %	146.5 %	140.8 %
Interest Received / Avg. Cash	3.4 %	3.3 %	1.4 %	0.8 %	0.6 %	0.6 %	0.5 %
Interest Paid / Avg. Debt	5.9 %	6.5 %	5.7 %	12.5 %	0.0 %	0.0 %	0.0 %
<b>Management of Funds</b>							
Investment ratio	21.9 %	22.2 %	20.5 %	19.5 %	14.9 %	14.0 %	13.6 %
Maint. Capex / Sales	21.2 %	22.3 %	21.4 %	19.1 %	14.3 %	13.3 %	12.9 %
Capex / Dep	107.0 %	35.8 %	46.2 %	87.3 %	63.2 %	59.6 %	57.9 %
Avg. Working Capital / Sales	16.9 %	25.0 %	27.1 %	24.2 %	19.1 %	15.0 %	13.9 %
Trade Debtors / Trade Creditors	376.6 %	390.2 %	378.4 %	341.2 %	291.7 %	253.8 %	261.5 %
Inventory Turnover	3.5 x	8.0 x	2.8 x	3.0 x	4.2 x	5.0 x	5.6 x
Receivables collection period (days)	111	131	118	107	91	80	80
Payables payment period (days)	891	697	599	780	1,043	959	850
Cash conversion cycle (Days)	-757	-635	-424	-621	-934	-869	-771

**CAPEX and Cash Flow**  
in EUR m**Free Cash Flow Generation****Working Capital**

Source: Warburg Research

Source: Warburg Research

Source: Warburg Research



**LEGAL DISCLAIMER**

This research report was prepared by the Warburg Research GmbH, a subsidiary of the M.M.Warburg & CO KGaA and is passed on by the M.M.Warburg & CO KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

**COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

**DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)**

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

**SOURCES**

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Section 34b of the German Securities Trading Act in combination with the FinAnV requires an enterprise preparing a securities analysis to point out possible conflicts of interest with respect to the company that is the subject of the analysis. A conflict of interest is assumed, in particular, when the enterprise preparing the analysis ...

- 1- ... or companies affiliated with this enterprise **holds 5%** or more of the share capital of the analysed company
- 2- ... or companies affiliated with this enterprise were involved in the management of a **consortium** for a public offering of securities which are or whose issuer is the subject of this report within the last twelve months
- 3- ... or companies affiliated with this enterprise **manages** the **securities** of the analysed company on the basis of an existing contract
- 4- ... or companies affiliated with this enterprise over the previous 12 months has been providing **investment banking services** for the analysed company for which a compensation has been or will be paid
- 5- ... effected an **agreement** with the analysed company **for the preparation of the financial analysis**
- 6- ... or companies affiliated with this enterprise **regularly trade** in shares or derivatives of the analysed company
- 7- ... or the analyst responsible for this company has **other important financial interests** in relation to the analysed company such as e.g. the performance of mandates for the analysed company

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
MeVis Medical Solutions	3, 5, 6, 7	<a href="http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0LBFE4.htm">http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0LBFE4.htm</a>

**INVESTMENT RECOMMENDATION**

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	<b>Buy:</b>	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	<b>Hold:</b>	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	<b>Sell:</b>	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	<b>Rating suspended:</b>	The available information currently does not permit an evaluation of the company.


**WARBURG RESEARCH GMBH – RESEARCH UNIVERSE BY RATING**

Rating	Number of stocks	% of Universe
Buy	99	50
Hold	85	43
Sell	12	6
Rating suspended	4	2
<b>Total</b>	<b>200</b>	<b>100</b>

**WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...**

... Looking only at companies for which a disclosure according to § 34b of the Germany Securities Trading Act and the FinAnV has to be made.

Rating	Number of stocks	% of Universe
Buy	84	54
Hold	63	40
Sell	6	4
Rating suspended	3	2
<b>Total</b>	<b>156</b>	<b>100</b>

**PRICE AND RATING HISTORY MEVIS MEDICAL SOLUTIONS AS OF 06.11.2013**

The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.

**RESEARCH**

<b>Roland Rapelius</b> Head of Research	+49 40 309537-220 rrapelius@warburg-research.com
<b>Henner Rüschemeyer</b> Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com
<b>Christian Cohrs</b> Engineering, Logistics	+49 40 309537-175 ccohrs@warburg-research.com
<b>Felix Ellmann</b> Software, IT	+49 40 309537-120 fellmann@warburg-research.com
<b>Jörg Philipp Frey</b> Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com
<b>Ulrich Huwald</b> Health Care, Pharma	+49 40 309537-255 uhuwald@warburg-research.com
<b>Thilo Kleibauer</b> Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
<b>Torsten Klingner</b> Real Estate	+49 40 309537-260 tklingner@warburg-research.com
<b>Eggert Kuls</b> Engineering	+49 40 309537-256 ekuls@warburg-research.com
<b>Frank Laser</b> Construction, Industrials	+49 40 309537-235 flaser@warburg-research.com
<b>Andreas Pläsier</b> Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com

<b>Malte Rätther</b> Technology, Telco, Internet	+49 40 309537-185 mraether@warburg-research.com
<b>Jochen Reichert</b> Telco, Internet, Media	+49 40 309537-130 jreichert@warburg-research.com
<b>Christopher Rodler</b> Utilities	+49 40 309537-290 crodler@warburg-research.com
<b>Malte Schaumann</b> Technology	+49 40 309537-170 mschaumann@warburg-research.com
<b>Susanne Schwartz</b> Telco, Internet, Media	+49 40 309537-155 sschwartz@warburg-research.com
<b>Oliver Schwarz</b> Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
<b>Marc-René Tonn</b> Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
<b>Björn Voss</b> Steel, Car Suppliers	+49 40 309537-254 bvoss@warburg-research.com
<b>Andreas Wolf</b> Software, IT	+49 40 309537-140 awolf@warburg-research.com
<b>Stephan Wulf</b> Utilities	+49 40 309537-150 swulf@warburg-research.com

**SALES**

<b>Holger Nass</b> Head of Equity Sales, USA	+49 40 3282-2669 hnass@mmwarburg.com
<b>Klaus Schilling</b> Dep. Head of Equity Sales, GER	+49 40 3282-2664 kschilling@mmwarburg.com
<b>Christian Alisch</b> Scandinavia, Spain	+49 40 3282-2667 calisch@mmwarburg.com
<b>Tim Beckmann</b> United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com
<b>Matthias Fritsch</b> United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com
<b>Marie-Therese Grübner</b> France	+49 40 3282-2630 mgruebner@mmwarburg.com
<b>Michael Kriszun</b> United Kingdom	+49 40 3282-2695 mkriszun@mmwarburg.com
<b>Marc Niemann</b> Germany	+49 40 3282-2660 mniemann@mmwarburg.com
<b>Dirk Rosenfelder</b> Austria, Switzerland	+49 40 3282-2692 drosenfelder@mmwarburg.com
<b>Philipp Stumpfegger</b> Australia, United Kingdom	+49 40 3282-2635 pstumpfegger@mmwarburg.com

**SALES TRADING**

<b>Oliver Merckel</b> Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com
<b>Gudrun Bolsen</b> Sales Trading	+49 40 3282-2679 gbolsen@mmwarburg.com
<b>Bastian Quast</b> Sales Trading	+49 40 3282-2701 bquast@mmwarburg.com
<b>Thekla Struve</b> Sales Trading	+49 40 3282-2668 tstruve@mmwarburg.com
<b>Jörg Treptow</b> Sales Trading	+49 40 3262-2658 jtreptow@mmwarburg.com

**Support**

<b>Katharina Merckel</b> Roadshow/Marketing	+49 40 3282-2694 kmerckel@mmwarburg.com
--	--

**MACRO RESEARCH**

<b>Carsten Klude</b> Macro Research	+49 40 3282-2572 cklude@mmwarburg.com
<b>Matthias Thiel</b> Macro Research	+49 40 3282-2401 mthiel@mmwarburg.com
<b>Dr. Christian Jasperneite</b> Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com

**Our research can be found under:**

Warburg Research	research.mmwarburg.com/en/index.html	Thomson	www.thomson.com
Bloomberg	MMWA GO	Reuters	www.knowledge.reuters.com
FactSet	www.factset.com	Capital IQ	www.capitaliq.com

**For access please contact:**

<b>Andrea Schaper</b> Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	<b>Kerstin Muthig</b> Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com
---	--	---	---